An interventional study of Nutrition Support Product in Irritable Bowel Syndrome, Crohn Disease and Ulcerative Colitis, sponsored by Metagenics, Inc.. Completed. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-04-06.
Sponsored by Metagenics, Inc. · Not applicable, Interventional, and Supportive care
This study assessed the effect of a nutrition support product on quality of life in adults with compromised gut function and malabsorption.
This prospective, non-randomized, open-label study assessed the effect of a nutrition support product on quality of life in adults with compromised gut function and malabsorption. Adults with irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) or celiac disease were enrolled in the study and asked to take the study product for 6 weeks. The primary measure of the study was a validated quality of life questionnaire, the Gastrointestinal Quality of Life Index (GIQLI). Secondary measures included the Inflammatory Bowel Disease Questionnaire (IBDQ), the Celiac Disease Questionnaire (CDQ), and the Digestive Symptom Frequency Questionnaire (DSFQ).
Exclusion Criteria:
Participants were asked to take a nutrition support product twice per day for a period of 6 weeks.
Other: Nutrition Support Product
Nutrition support product contains macronutrients, micronutrients, glutamine, and prebiotics. Product is in powder form (41 grams per serving) and is mixed with water or juice before consumption. Taken orally as a nutritional shake twice per day.
Also known as: UGIR
Change in Gastrointestinal Quality of Life Index (GIQLI) Score
Time frame: 6 weeks
Change in Inflammatory Bowel Disease Questionnaire (IBDQ) Score
Time frame: 6 weeks
Change in Celiac Disease Questionnaire (CDQ) Score
Time frame: 6 weeks
Change in Digestive Symptom Frequency Questionnaire (DSFQ) Score
Time frame: 6 weeks
No study locations are listed for this record.
Plan to share: No
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Metagenics, Inc.